-
LAMP1, CXCL10–CXCR3, and Macrophage Polarization
2026-09-11
The reference study identifies LAMP1-dependent autophagy as a context-sensitive switch that determines whether CXCL10–CXCR3 signaling promotes M1 or M2 macrophage polarization. Its combination of macrophage perturbation experiments and a Poly(I:C)-induced mouse lung-injury model links this mechanism to inflammatory disease biology and suggests CXCR3 antagonism as a testable intervention.
-
ISG20 in Atherosclerosis: From Causality to Imaging
2026-09-11
Causal genetic evidence is most valuable when it can be translated into spatially resolved, reproducible biology. This article examines how ISG20 and CLEC5A findings in atherosclerosis can inform immunofluorescence, immunohistochemistry, flow cytometry, and assay-design strategy using the HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody.
-
FPS-ZM1: Dissecting RAGE Across CNS Models
2026-09-10
FPS-ZM1 is a selective RAGE inhibitor for separating amyloid beta (Aβ) transport, neuroinflammation, and metabolic stress mechanisms in CNS research. This article translates new RAGE/POMC findings into a rigorous assay strategy without treating berberine activity and pharmacological RAGE blockade as equivalent.
-
CCK-8s, NOX4, and ANP Secretion in Rat Atria
2026-09-10
The 2022 reference study identifies a signaling route through which sulfated cholecystokinin octapeptide stimulates atrial natriuretic peptide secretion in isolated beating rat atria. Its main contribution is to connect CCK receptor activation with arachidonic acid release, NOX4-derived hydrogen peroxide, PGC-1α, and PPARα/PPARγ signaling while showing that ANP feeds back on oxidative signaling.
-
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody Guide
2026-09-09
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody provides fluorescent detection of rabbit IgG primary antibodies in immunofluorescence, fluorescent IHC, ICC, and flow cytometry workflows. It should be optimized for each assay and is not intended for diagnostic use, unvalidated live-cell exposure, or detection of non-rabbit primary antibodies.
-
Hoechst 33342 in Fibroblast Senescence Assays
2026-09-09
Build reliable live-cell, fixed-cell, microscopy, and flow-cytometry workflows around a permeable DNA stain. The approach turns nuclear labeling into a practical normalization layer for studying pterostilbene, mitochondrial quality, and dermal fibroblast senescence.
-
Albiflorin in RCC: Integrated Experimental Evidence
2026-09-08
This study combines cell-based assays, network pharmacology, molecular docking, RT-qPCR, and protein analysis to investigate albiflorin in renal cell carcinoma. The findings identify EGFR/MAPK signaling and progression-related molecules as plausible components of its activity, while also illustrating how transcript and phosphorylation measurements can be integrated to evaluate mechanism.
-
Poly (I:C) for TLR3 Immune Assays
2026-09-08
Poly (I:C) provides a practical TLR3-centered input for interferon assays, dendritic cell maturation studies, and controlled innate-to-adaptive immune modeling. This guide connects product handling with the CGRP–RAMP1 findings in allergic sensitization research while separating established evidence from hypothesis-generating extensions.
-
CA-074 Me: Cathepsin B Inhibitor Guide
2026-09-07
CA-074 Me is a membrane-permeable cathepsin B inhibitor with a reported biochemical IC50 of 36.3 nM. It supports lysosomal enzyme inhibition, apoptosis assay design, necroptosis studies, and TNF-α-induced liver injury model research, but reducing conditions can compromise its cathepsin B selectivity.
-
GANT61 GLI Inhibitor: Assay Workflows
2026-09-07
GANT61 is a practical GLI inhibitor for separating Hedgehog-pathway transcriptional effects from upstream signaling events. This guide translates its use into cell, tumor–immune, and in vivo workflows while emphasizing solubility control, target-engagement readouts, and limits when modeling immunotherapy resistance.
-
Cyclo (-RGDfC) for Reliable Cell Assays
2026-09-05
Learn how Cyclo (-RGDfC) (SKU A8790) can support controlled integrin αvβ3 targeting, cell-adhesion studies, and cancer research workflows. This scenario-based guide covers formulation, assay compatibility, protocol planning, interpretation, and practical product-selection criteria.
-
DRP1-Driven Mitochondrial Fission in Hyperoxic ATII Cells
2026-09-04
Sun et al. identify activated DRP1 as a mechanistic link between mitochondrial fragmentation and glycolytic reprogramming in alveolar type II cells exposed to hyperoxia. By combining neonatal rat experiments, cell models, mitochondrial imaging, Seahorse analysis, and pharmacological inhibition, the study provides a framework for investigating metabolic injury in bronchopulmonary dysplasia.
-
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody Guide
2026-09-04
The Cy3 Goat Anti-Rabbit IgG (H+L) Antibody provides fluorescent detection of rabbit primary antibodies in immunofluorescence, fluorescent IHC, ICC, and compatible flow cytometry workflows. It should be validated for assay-specific dilution, optical settings, and sample background, and its sodium azide-containing formulation is not intended for direct live-cell use without appropriate buffer exchange.
-
Berberine, RAGE/POMC, and Metabolic Control
2026-09-03
A 2026 pre-proof study identifies RAGE as a central nervous system target of berberine within Tianhuang Formula and links RAGE/POMC signaling to hypothalamic neuronal apoptosis, autophagy, and glucolipid metabolism. Its integrated computational, cellular, and mouse-model design offers a mechanistic framework for studying neuronal regulation of metabolic disease while leaving questions about causality, dosing, and clinical translation unresolved.
-
Toremifene Citrate: Applied Research Workflows
2026-09-03
Build reproducible estrogen receptor assays with Toremifene Citrate, from DMSO stock preparation through MCF-7 proliferation and pathway readouts. The workflow emphasizes concentration selection, vehicle controls, receptor-context validation, and translational interpretation for breast cancer research.